Search | Clinical Trials Finder

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions: ALXN2220; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 35
States / cities: Irvine, California • La Jolla, California • Palo Alto, California + 29 more

Conditions: Transthyretin Amyloidosis With Cardiomyopathy
Interventions: Nucresiran, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 42
States / cities: La Jolla, California • Laguna Hills, California • Stanford, California + 35 more

Conditions: Amyloid Cardiomyopathy, Transthyretin-Related
Interventions: Acoramidis (AG10); Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 26
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more

Conditions: Amyloidosis, Transthyretin Amyloid Cardiomyopathy
Interventions: 99m-technetium pyrophosphate scintigraphy; Diagnostic Test
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 60 Years to 90 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
Interventions: Scintigraphy; Diagnostic Test
Lead sponsor: Pfizer; Industry
Eligibility: 60 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 22
States / cities: Fairhope, Alabama • Huntsville, Alabama • Miami, Florida + 11 more

Conditions: Familial Amyloidotic Cardiomyopathy (FAC)
Interventions: Not listed
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 43
States / cities: Little Rock, Arkansas • Bakersfield, California • La Mesa, California + 32 more

Conditions: Transthyretin Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy
Interventions: 99mTc-pyrophosphate Single Photon Emission Computed Tomography; Diagnostic Test
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Interventions: Eplontersen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 46
States / cities: Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 35 more

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: NTLA-2001, Placebo; Biological · Drug
Lead sponsor: Intellia Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 38
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Interventions: NNC6019-0001; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • Stanford, California + 5 more

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: Placebo, Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 19
States / cities: Los Angeles, California • Chicago, Illinois • Skokie, Illinois + 14 more

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions: Tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 41
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 20 more

Conditions: Cardiomyopathies, Primary
Interventions: (18F)Flutemetamol; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions: Tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: TTR Cardiomyopathy
Interventions: Period 1, Period 2, Period 3; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
Interventions: Exercise Training; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Interventions: Eplontersen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 51
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 39 more

Conditions: Cardiomyopathy
Interventions: Fx-1006A; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases
Interventions: acoramidis, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 40
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 32 more

Conditions: Amyloidosis
Interventions: Inotersen; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)
Interventions: AG10, Placebo Oral Tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 13
States / cities: Beverly Hills, California • Palo Alto, California • San Francisco, California + 9 more

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions: Eplontersen, ALXN2220, Placebo; Drug · Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 24
States / cities: La Jolla, California • San Francisco, California • Stanford, California + 21 more

Conditions: ATTR, ATTR Gene Mutation, Cardiomyopathy, Transthyretin Mediated Amyloidosis (ATTR)
Interventions: Iodine-124 Evuzamitide (I-124E); Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 30 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: ATTR-CM
Interventions: Machine learning algorithm; Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

carDIo-ttranSSfOrm nucLEar Imaging Study

Global Prevalence of ATTR-CM in Participants With HFpEF

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Bronx Transthyretin Amyloid Cardiomyopathy Database

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

Exercise Training in Transthyretin Cardiac Amyloidosis

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

Study of AG10 in Amyloid Cardiomyopathy

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

PET/CT Imaging in Carriers of TTR Mutations

A Retrospective Validation Study To Identify Chart-Based Clinical Diagnosis Of Wild-Type Transthyretin Amyloid Cardiomyopathy (Attrwt-CM) And Non-Amyloid Heart Failure Among Patients With Heart Failure (HF).